Head and Neck Cancer
Scottsdale, AZ—Definitive chemoradiation with single-agent outpatient chemotherapy for head and neck cancer led to disease control and survival equivalent to that of inpatient multi-agent therapy, at an annualized savings of almost $650,000, according to results of a small randomized trial presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Berlin, Germany—Although little is known about the prevalence of lymphedema in patients with head and neck cancer, a series of studies showed that 75% of patients with head and neck cancer have problematic lymphedema internally and externally.
New Calculator Shows Financial Impact of Poor Quality of Care to an Institution, and How to Correct It
Toronto, Canada—A Healthcare Quality Calculator (HQCal) created by researchers at Vanderbilt University School of Medicine, Nashville, TN, allows decision makers to determine which investments are the most cost-efficient for improving quality of care, according to a new study presented at the 2012 International Conference on Head and Neck Cancer.
Use of Intensity-Modulated Radiotherapy Increasing and Costly in the Management of Head and Neck Cancers, but Value Unknown
Toronto, Canada—The popularity of intensity-modulated radiotherapy (IMRT) for head and neck cancer has climbed rapidly in recent years. However, the extra cost associated with this treatment modality may not equate with improved value, according to researchers from the University of California at Los Angeles (UCLA), who presented their analysis at the 2012 International Conference on Head and Neck Cancer.
Results 1 - 5 of 5